THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY

被引：0
|
作者：
Tam, C. [1 ]
Roberts, A. [2 ]
Anderson, M. A. [2 ]
Dawson, S. J. [1 ]
Hicks, R. [1 ]
Pott, C. [3 ]
Westerman, D. [1 ]
Burke, G. [1 ]
Kamel, S. [4 ]
Dreyling, M. [5 ]
Dawson, M. [1 ]
Seymour, J. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia
[2] Melbourne Hlth, Parkville, Vic, Australia
[3] Univ Hosp Schleswig Holstein, Kiel, Germany
[4] St Vincents Hosp, Melbourne, Vic, Australia
[5] Univ Munich, Munich, Germany
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P316
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [11] Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
    Portell, Craig A.
    Wages, Nolan A.
    Kahl, Brad S.
    Budde, Lihua E.
    Chen, Robert W.
    Cohen, Jonathon B.
    Varhegyi, Nikole E.
    Petroni, Gina R.
    Williams, Michael E.
    BLOOD ADVANCES, 2022, 6 (05) : 1490 - 1498
  • [12] Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Nishikawa, Tomoaki
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (02) : 98 - 100
  • [13] A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma
    Kim, Myung Sun
    Banerjee, Titas
    Chen, Andy
    Danilov, Alexey
    MacKinnon, Renee
    Thurlow, Bria
    Thakurta, Sujata
    Orand, Kirsten
    Degnin, Catherine
    Park, Byung
    Spurgeon, Stephen E.
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 722 - 724
  • [14] VENETOCLAX (ABT-199/GDC-0199) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 1B RESULTS
    Moreau, P.
    Chanan-Khan, A. A.
    Roberts, A.
    Agarwal, A.
    Facon, T.
    Lebovic, D.
    Touzeau, C.
    Darden, D.
    Morris, L.
    Ross, J.
    Salem, A.
    Munasinghe, W.
    Zhu, M.
    Leverson, J.
    Enschede, S.
    Humerickhouse, R.
    Harrison, S.
    HAEMATOLOGICA, 2015, 100 : 91 - 92
  • [15] Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
    Wang, Michael
    Jurczak, Wojciech
    Trneny, Marek
    Belada, David
    Wrobel, Tomasz
    Ghosh, Nilanjan
    Keating, Mary-Margaret
    van Meerten, Tom
    Alvarez, Ruben Fernandez
    von Keudell, Gottfried
    Thieblemont, Catherine
    Peyrade, Frederic
    Andre, Marc
    Hoffmann, Marc
    Glusman, Edith Szafer
    Lin, Jennifer
    Dean, James P.
    Neuenburg, Jutta K.
    Tam, Constantine S.
    BLOOD, 2023, 142
  • [16] Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
    Wang, Michael
    Jurczak, Wojciech
    Trneny, Marek
    Belada, David
    Wrobel, Tomasz
    Ghosh, Nilanjan
    Keating, Mary-Margaret
    van Meerten, Tom
    Fernandez Alvarez, Ruben
    von Keudell, Gottfried
    Thieblemont, Catherine
    Peyrade, Frederic
    Andre, Marc
    Hoffmann, Marc
    Glusman, Edith Szafer
    Lin, Jennifer
    Dean, James P.
    Neuenburg, Jutta K.
    Tam, Constantine S.
    BLOOD, 2024, 144 : LBA5 - LBA5
  • [17] Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study
    Tam, Constantine S.
    Ramchandren, Radhakrishnan
    Chen, Robert
    Karlin, Lionel
    Chong, Geoffrey
    Jurczak, Wojciech
    Wu, Ka Lung
    Bishton, Mark
    Collins, Graham P.
    Eliadis, Paul
    Peyrade, Frederic
    Szafer-Glusman, Edith
    Lee, Yihua
    Eckert, Karl
    Neuenburg, Jutta K.
    Wang, Michael
    BLOOD, 2020, 136
  • [18] A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
    de Vos, Sven
    Swinnen, Lode
    Kozloff, Mark
    Wang, Ding
    Reid, Erin
    Nastoupil, Loretta
    Fowler, Nathan
    Cordero, Jaclyn
    D'Amico, Diane
    Diehl, Susan
    Dunbar, Martin
    Zhu, Ming
    Wong, Shekman
    Enschede, Sari Heitner
    Chien, David
    Humerickhouse, Rod A.
    Flowers, Christopher
    BLOOD, 2015, 126 (23)
  • [19] Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial
    Wang, Michael
    Hagemeister, Fredrick
    Westin, Jason R.
    Fayad, Luis
    Samaniego, Felipe
    Turturro, Francesco
    Chen, Wendy
    Zhang, Liang
    Badillo, Maria
    DeLa Rosa, Maria
    Addison, Alicia
    Kwak, Larry W.
    Romaguera, Jorge E.
    BLOOD, 2014, 124 (21)
  • [20] Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Darden, David
    Morris, Lura
    Ross, Jeremy
    Salem, Ahmed H.
    Munasinghe, Wijith
    Zhu, Ming
    Leverson, Joel
    Maciag, Paulo
    Enschede, Sari Heitner
    Verdugo, Maria
    Humerickhouse, Rod A.
    Harrison, Simon
    BLOOD, 2015, 126 (23)
12345